Patients have long been working their way upstream in drug research. At last they are up the creek with a paddle. #publicinvolvement #patient-centricity

Patients and carers will tell you that all that is good or bad about health research can usually be traced to its source. That place where the idea is first formed by scientists. Eureka moment it might be, they will say, but having patients and carers involved from the beginning can save embarrassment for all... Continue Reading →

Excellent new guidance published to help charities and pharma work together with the public’s trust @ABPI_UK @NVTweeting

It's high time we got over it. Pretending it doesn't go on is foolish. Suspecting the worst every time they come near to one another is energy-sapping. No one is trying to deny history. But we are in danger of denying others a future if we continue to stand in their way. I mean, of... Continue Reading →

The truth, the whole truth and nothing but….pharma

Here is a gripping report from this week's 'Adweek' (based in New York) about the new marketing strategies being used by pharmaceutical companies. Don't be put off by the reference to 'Obamacare.' The story is equally applicable to the United Kingdom.  For it is essentially a tale about how disease is being re-packaged. Patient data is the new... Continue Reading →

Patient View Report: Pharma industry’s lack of transparency harming reputation with patients

Earlier this week Patient View published the results of its annual tracker of the pharmaceutical industry's reputation among patient groups. The latest study surveyed 600 patient groups (72% of them from Europe). As well as asking patient groups to rank 29 pharmaceutical companies by various indices (such as whether their practices were patient-centred) - Lundbeck... Continue Reading →

European patient group directory has some way to go before showing full story on pharma funding

My good colleagues at Cancer52 (the rare cancers coalition) sent me this, the third edition of the Burson-Marsteller directory of patient groups. On a purely practical level this tome is vital in helping to find your way round the various patient groups working on the European stage. Note the introduction by the EU Health Commissioner,... Continue Reading →

UKCMRI Task Gets Bigger

So the UKCMRI partners were in front of the House of Commons Science and Technology Committee yesterday as were representatives of the local community.  Meanwhile the Science Minister, David Willetts, announced that the Government had agreed the business plan for the new centre as put forward by the Medical Research Council (MRC).   A good day all... Continue Reading →

When good medicine is the casualty of hype and ignorance

I have just returned from the Financial Times' offices, where I was the guest for their regular science podcast hosted by Clive Cookson and Andrew Jack (it will appear here later today).  The theme of the discussion was 'Selling Sickness.'  Andrew was reporting on a recent conference of the same name that took place last month in Holland. ... Continue Reading →

Public, private and charitable research: the spillover effect

RAND Europe and the Office of Health Economics (OHE) last week published this rather fascinating occasional paper from a seminar in May.  It examines the spillovers (wider benefits) from biomedical and health research and seems highly salient given what is going on.  I thought some of the diagrams were helpful in visualising the multilying effect of... Continue Reading →

Science at the Conservative Party Conference – it ain't over until it's over

'So we will give priority to spending that supports growth in our economy. That means investment in the transport schemes, the medical research and the communications networks that deliver the greatest economic benefit.' George Osborne, 4 October 2010 Welcome, good, important? Yes. Victory, game over? Of course not. A noticeable frisson went through the room... Continue Reading →

Blog at WordPress.com.

Up ↑

%d bloggers like this: